TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04988555: A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sponsor: Sumitomo Pharma America, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 606 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT04988555 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04988555 Rescue Dossier →